Cargando…
Combined effects of the hedgehog pathway inhibitor LDE225 and nilotinib in a random mutagenesis screen
Autor principal: | Tauchi, Tetsuzo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3332451/ http://dx.doi.org/10.1186/ar3598 |
Ejemplares similares
-
Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia
por: Irvine, David A., et al.
Publicado: (2016) -
Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy
por: Ross, Ashley E., et al.
Publicado: (2017) -
Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells
por: D'Amato, C, et al.
Publicado: (2014) -
Do LDE-Methotrexate lipid nanoparticles decrease allograft vasculopathy in rabbit transplanted heart ?
por: Stolf, N, et al.
Publicado: (2013) -
Phase I/II Study of LDE225 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer
por: Pijnappel, Esther N., et al.
Publicado: (2021)